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ABSTRACT

DIVERGENT ROLES OF PI3K AND AKT IN
RAPAMYCIN-INDUCED CARDIOPROTECTION
AGAINST ISCHEMIA-REPERFUSION INJURY

By Shivani K. Desai, B.S.
A thesis submitted in partial fulfillment of the requirement for the degree of Masters of
Science in Physiology at Virginia, Virginia Commonwealth University.
Virginia Commonwealth University, 2007
Major Director: Dr. Rakesh C. Kukreja, Ph.D.
VCU School of Medicine
Division of Cardiology

Coronary heart disease (CHD) is one of the leading causes of death every year
with nearly three-fourths of all deaths caused by the disease. The challenge scientists are
facing today is discovering new drugs to protect the heart against cellular damage caused
by ischemia-reperfusion injury (I-R injury). Rapamycin is one such drug that has been
shown to protect the heart against ischemia-induced cellular injury. Rapamycin

ix

x
(sirolimus) inhibits protein synthesis through inhibition of the mammalian target of
rapamycin (mTOR). This property of rapamycin has led to its current clinical
applications in drug-eluting stents and in immunosuppresive treatment to organ transplant
patients. The mechanism by which this drug protects against I-R injury is currently
unknown. The goal of this study is to elucidate rapamycin’s cardioprotective signaling
pathway. We hypothesized that upregulation of Akt occurs possibly as part of a positive
feedback mechanism following the inhibition of mTOR by rapamycin. Adult male ICR
mice were treated with rapamycin (0.25 mg/kg, i.p.), or volume-matched DMSO (solvent
for rapamycin), or rapamycin (0.25mg/kg, i.p.) plus wortmannin (WTN, 15µg/kg, i.p.),
an inhibitor of phosphatidylinositol 3-kinase, or wortmannin alone (15µg/kg, i.p.). After
30 min of stabilization, the hearts were subjected to 20 minutes of global ischemia and 30
minutes of reperfusion in Langendorff model. In a separate series of experiments mice
were either injected with DMSO or rapamycin for 30 minutes, 1 hour, and 2 hours before
harvesting the hearts for Western blot analysis of levels of total or phosphorylated Akt at
473
Ser . Our results showed that rapamycin protected the heart as observed by a reduction

in infarct size from 33.8 ± 2.0% in DMSO-treated hearts to 19.3 ± 4.1% in rapamycintreated hearts; a 43% reduction. This infarct-limiting effect was completely blocked by
wortmannin (29.3 ± 4.8%). However, Western blot analysis showed no change in the
level of Akt phosphorylation after administration of rapamycin. Our current results
further confirmed rapamycin as a potential cardio-therapeutic drug to limit infarct size,
potentially through the PI3K signaling pathway. However, the exact signaling pathway of
this protection still remains elusive.

INTRODUCTION

1.1 Coronary Heart Disease
In 2004, the American Heart Association determined coronary heart disease
(CHD), the cause of heart attacks and angina, to be the single leading cause of death in
America. About 325,000 people a year die of CHD which is nearly 75% of all deaths. All
in all, that is nearly 900 Americans each day, most of whom die from sudden cardiac
arrest. Acute coronary occlusion is expected to be the major cause of death by the year
2020 according to the World Health Organization (19; 60). With this meek prediction,
new medical therapies are urgently needed to deal with the consequences of CHD in
order to reduce the global impact of this disease.
As mentioned, CHD is the cause of heart attacks or myocardial infarctions which
occur when there is a sudden occlusion of one or more of the coronary arteries. This
blockage reduces or eliminates the flow of oxygenated blood to the myocardium
normally supplied by the occluded vessel. Myocardial infarctions are usually caused by a
condition called atherosclerosis, a buildup of cholesterol and fibrous tissue in the form of
plaques on artery walls. The plaques may rupture the artery, causing a blood clot or
thrombus to form and block the artery. The lack of blood flow and oxygen is called
ischemia and if maintained for more than a few minutes, an ischemic cascade is triggered
in which myocytes suffer permanent damage and die mainly through necrosis. As the
division of surrounding myocytes cannot replace these dead myocytes, the
1
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preservation of myocardium’s viability after ischemia has become a major target for
therapeutic research (60).

1.2 Reperfusion injury
In an effort to find a therapy to limit infarct size, in 1983 Jennings and Reimer
demonstrated that reperfusion of the occluded vessels was essential to protecting the
ischemic myocardium (21). Thereafter, therapies such as thrombolysis (19), anti-platelet
therapy (22) and primary angioplasty (19; 32) were used in the clinical setting to reestablish coronary blood flow. Paradoxically, reperfusion therapy itself results in
cardiomyocyte death, an inherent phenomenon termed reperfusion injury.
Reperfusion injury causes rapid disruption of heart tissue as shown by the release
of cytosolic enzymes and changes in the microscopic structure of the myocytes. Two
forms of cell death have been implicated with reperfusion (17). Studies have identified
necrosis as one of these forms of cell death, involving tissue edema, matrix degradation,
cell lysis and fragmentation, and inflammation (1; 19; 54). Reperfusion also produces a
burst of free radical oxidative species and calcium overload (3), which contributes to
necrosis (54). Apoptotic cell death is also either triggered or exacerbated during
reperfusion (1). This finding is supported by the fact that apoptosis is an ATP-dependent
process and diminished ATP levels due to ischemia are restored during reperfusion (19).
Although the restoration of blood flow was an important area of investigation, in order to
reduce infarct size, discovering new means of cell protection became one of the focused
topics in cardiovascular research.

3
1.3 Ischemic preconditioning
Knowledge about ischemia-reperfusion injury until the mid-1980s had led
scientists to believe that a brief period of ischemia sublethally injured the myocardium
and made it more sensitive to subsequent periods of ischemia, culminating in infarction.
Then, in 1986, Murry et al. discovered that not all myocardial ischemia is harmful. The
phenomenon of ischemic preconditioning (IPC) was found in which brief periods of
ischemia actually protect the heart against subsequent prolonged ischemia (32; 36; 59;
60). This intrinsic protection has been found to have a biphasic window: an early phase or
classical preconditioning that last up to ~2 hours after the preconditioning stimulus
followed a day later by a delayed phase or second window of protection (SWOP) lasting
~3days (34; 42; 57; 60).
By effectively reducing both necrosis (32; 59) and apoptosis within an infarcted
heart (57), IPC increases the time available for effective reperfusion. Patients with
unstable angina and those undergoing bypass surgery or coronary angioplasty can benefit
from preconditioning (32). Furthermore, this phenomenon has been shown to occur in all
species tested including man and with a very similar reduction in infarct size in all
species (42). For these reasons, IPC has been recognized as “the strongest form of in vivo
protection against myocardial ischemic injury other than early reperfusion” (28).
Remarkably, the cardioprotective effects of IPC can be induced through the
administration of exogenous pharmacological agents such as bradykinin (32; 42),
adenosine (42), opioids (42), erythropoietin (15), acetylcholine (6; 42), and nitric oxide
(NO) (31). Mitochondrial KATP channel openers (1; 39; 58), HMG-CoA reductase
inhibitors such as simvastatin (23) and atorvastatin (11), phosphodiesterase 5 inhibitors
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such as sildenafil (40), and certain volatile anesthetics including desflurane (52) and
isoflurane (29) can also mimic IPC’s effects. These mimetics have been discovered over
the past two decades through investigation of the diverse signaling pathways involved in
the biochemical mechanism of IPC and allow us to prolong the short-lived effects of
acute IPC (57).

1.4 Phosphatidylinositol 3-kinase/Akt signaling pathway
Tong et al. were the first to implicate the activation of the phosphatidylinositol 3kinase (PI3K)/Akt signaling pathway during IPC (55; 56). PI3K, a lipid kinase (2), has a
vital role in mediating many cellular responses in both physiologic and pathophysiologic
states such as cell cycle progression, differentiation, and survival (14). Stimulation of cell
surface receptors activates PI3K, which then itself phosphorylates membrane
phophoinositides at the D-3 position. These phospholipids act as second messengers that
mediate the diverse cellular functions of PI3K (2; 24). One function of these second
messengers is the activation of the serine/threonine kinase Akt, another name for which is
protein kinase B (7). Akt contains a pleckstrin homology domain on its amino terminus
that directly binds the phospholipid products of PI3K. As a result, Akt is recruited from
its cytoplasmic location to the membrane where these PI3K products are located (53).
This allows a conformational change in the PI3K products, enabling the phosphorylation
of Akt by the phosphoinositide-dependent kinases 1 (PDK1) and PDK2 at residues Thr308
473
and Ser , respectively. Full activation of Akt is due to the phosphorylation of these two

residues (2; 14; 24; 27). In turn, activated Akt phosphorylates a number of downstream
targets.
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1.5 Akt signaling effects
Akt is a multifunctional protein kinase with diverse downstream target effects that
can be roughly divided into three groups: 1) anti-apoptotis/cell survival, 2) cellular
growth and metabolism, and 3) increased translation. The cardioprotective effects of Akt
activation have been mainly attributed to the reduction of myocardial apoptosis. Akt’s
anti-apoptotic actions involve both cytoplasmic and nuclear compartments (7). Akt
phosphorylates the protein BAD at Ser136 (22) which inhibits BAD’s pro-apoptotic
activity by reducing its inhibition of the anti-apoptotic proteins, Bcl-2 and Bcl-XL (41; 53;
57). Other targets include the forkhead transcription factors: FKHR, FKHR-L1, and
AFX, which are all, down-regulated when Akt phosphorylates them (2; 41). For example,
phosphorylation of FKR-L1 retains it in the cytoplasm through sequestration by 14-3-3
proteins and prevents it from activating transcription of pro-apoptotic genes (53).
Akt also promotes cell survival by maintaining the integrity of the outer
mitochondrial membrane. By doing so, cytochrome c release into the cytosol is
prevented. Normally if cytochrome c were allowed to be released into the cytosol, it
would bind to and activate the apoptotic protease-activating factor (Apaf-1), which in
turn cleaves and activates caspase-9, resulting in the activation of caspase-3 and caspase7. At this point the cells are committed to apoptosis (24; 43; 57). As for Akt target
effectors in the nucleus, Akt activates IκB kinases that degrade the inhibitory protein
IκB. IκB keeps the transcription factor, nuclear factor-κB (NF-κB), in the cytoplasm.
Once released, NFκB is free to migrate to the nucleus and regulate transcriptional activity
of inhibitor-of-apoptosis proteins (IAPs) (41; 53).
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Akt has many other cardiovascular functions by activating proteins that regulate
cellular proliferation, migration, and growth (41; 49). Glycogen synthase kinase 3
(GSK3β) is a growth inhibitory protein (2) and well-defined direct target of Akt. When
Akt phosphorylates GSK3β, it reduces its kinase activity (49), thus promoting glycogen
synthesis (50). Past studies suggest that an increase in cardiac glycogen might increase
resistance to cellular hypoxia during ischemia by providing a greater pool of fuel reserve
for anaerobic glycolysis (53).
Akt also has a key role in vascular homeostasis and angiogenesis (1; 50; 57).
Several stimuli in endothelial cells activate the PI3K/Akt signaling axis and regulate
endothelial cell survival, migration, and capillary-like structure formation, all important
steps in angiogenesis. Additionally, Akt controls NO synthesis by phosphorylating
endothelial nitric oxide synthase (eNOS), which has been associated with delayed
preconditioning (26). An increase in NO synthesis results in regulation of cardiovascular
homeostasis, vessel integrity, and vasomotor tone by increasing resting blood vessel
diameter and blood flow (50). Finally, a recent study demonstrated a marked increase in
heart size in mice expressing constitutively active Akt (49). This finding exemplifies
Akt’s promotion of organ growth in vertebrates. Moreover, Akt’s role in angiogenesis
implies that it must regulate this process during organ enlargement (50).
The cardioprotective effect of Akt activation after transient ischemia (33) may
render it a critical control point determining not only cardiomyocyte survival but,
function as well. Oudit et al. found constitutively active Akt genes to be influential on
myocardial contractile force although the effects were variable (41). This ultimately
makes Akt an important target for therapy in ischemic heart disease. The time dependent
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activation of Akt by IPC mimetics has been researched in the past. Ahmad et al. (1) and
Wang et al. (58) tested the time-dependency of Akt phosphorylation by BMS-191095 and
diazoxide, respectively. BMS-191095 and diazoxide are two mitoKATP channel openers
known to protect the heart against I-R injury. It has already been shown that a variety of
agents mimicking IPC are able to minimize I-R injury by the activation of prosurvival
kinases. Yellon et al. demonstrated the cardioprotective effect of atorvastatin given at the
commencement of reperfusion in the intact mouse heart and associated this protection
with the upregulation of PI3K/Akt (11).

1.6 Mammalian target of rapamycin
A final Akt downstream target, the mammalian target of rapamycin (mTOR), is a
289-kDa serine/threonine kinase. Akt activation of mTOR via phosphorylation (38) leads
to an altered metabolism and increased growth mediated by changes in gene transcription
and translation. Activated mTOR can phosphorylate and thereby inactivate the eukaryotic
translation initiation factor called 4E-binding protein 1 (4E-BP1), resulting in increased
protein translation (2; 3; 50). mTOR also phosphorylates and activates ribosomal protein
70S6 kinase (p70S6K) at Thr

389

(14; 18). Activated p70S6K phosphorylates ribosomal

protein S6 which increases the translation of 5’–terminal oligopyrimidine (TOP) tract
mRNAs, thus enhancing the synthesis of translational machinery (2; 49; 50). Like Akt,
p70S6K also inactivates the pro-apoptotic peptide, BAD (16), by phosphorylating its
Ser

136

residue (22). These effects are crucial to cellular growth and enhancing protein

synthesis. However, the present study centers on the inhibition of mTOR by the drug,
rapamycin.
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1.7 Rapamycin
Rapamycin is a macrolide ester (38) produced by a strain of Streptomyces
hygroscopicus which was isolated in 1975 from a soil sample collected from Rapa Nui,
better know as Easter Island. These days, the natural product has the generic name
sirolimus and has acquired the trademark name Rapamune® (47; 48). It was first isolated
as an antifungal agent however, additional studies have shown the drug to have antitumor and immunosuppressive effects (3; 10). Rapamycin’s clinical relevance includes
its ability to prevent restenosis, a prevalent side-effect after angioplasty surgery that
occurs in 30% to 60% of patients within the first six months. Because the drug is released
locally, sirolimus-coated stents effectively reduce the rate of restenosis (41; 51). The
antibiotic’s unique mechanism of action has caused it to pass clinical trials and is today
approved as an immunosuppressive therapy in organ transplantation (47; 48).
Rapamycin is known to bind with high affinity to its intracellular receptor, the
immunophilin (2) FK506-binding protein FKBP12. This complex binds to mTOR,
inhibiting its function and allowing dephosphorylation of p70S6K and 4E-BP1 (3; 20).
Literature has shown results which suggest that inactivating mTOR/p70S6K may mediate
the beneficial effects of preconditioning and several preconditioning mimetic drugs. One
study found that the inhibition of p70S6K prevented the phosphorylation of BAD and
blocked cell survival induced by insulin-like growth factor 1(IGF-1) (16). Another study
demonstrated how prolonged activation of p70S6K can cause cardiac hypertrophy (46),
suggesting that inhibiting the mTOR/p70S6K complex with rapamycin may have
beneficial cardiovascular effects (13; 26).
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Our lab (Khan et al.) was the first group to demonstrate the cardioprotective effect
of rapamycin against I-R injury in the isolated mouse heart and in cardiac myocytes
subjected to hypoxia-reoxygenation injury (13; 25). A significant reduction in infarct size
was observed but, there was no improvement in heart function. In support of this result,
another group discovered rapamycin’s ability to inhibit apoptosis by inhibiting
phosphorylation of p53 which blocks the transcriptional activation of pro-apoptotic
proteins such as Bax and the activation of the mitochondrial cell death process (5).
The drug’s effect seems to be dose-dependent as lower doses (1 nM) blocked
protection. In this study we used a previously reported cardioprotective dose (0.25mg/kg)
(25). In most studies that show rapamycin to block cardioprotection, the drug is
administered at or before reperfusion. In our previous study, rapamycin was administered
as a pretreatment (25). All in all, drugs that inhibit mTOR such as rapamycin may have
either beneficial or harmful effects depending on the dose and timing of administration
(13).

1.8 Present study
The aim of this study is to understand the role of PI3K/Akt phosphorylation in the
cardioprotection of rapamycin and better understand why the drug has varying effects.
We hypothesize that rapamycin could possibly influence the cross-talk between the
survival kinases whereby inhibition of mTOR may result in the upregulation of other
prosurvial knases such as Akt. Until recently, it was thought that Akt directly
phosphorylated its downstream target mTOR (38). Interestingly, research has proved Akt
to remain active following treatment of rapamycin (20). This could indicate one of two
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things: either a possible Akt-independent mechanism for mTOR phosphorylation or a
possible positive feedback loop from rapamycin-inactivated mTOR to Akt. A study in
2005 demonstrated that blocking the PI3K/Akt/mTOR pathway results in the partial
reduction of the development of cardiac hypertrophy in vivo (14). In order to test the role
of PI3K, we used wortmannin (WTN). WTN inactivates PI3Ks by covalent modification
of the catalytic subunit p110 (41). We used our well-established Langendorff isolated
perfused mouse heart model of global ischemia-reperfusion, which has been used
extensively to probe the therapeutic efficacy of drugs.
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Figure 1:
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MATERIALS AND METHODS

2.1 Animals
Adult male ICR mice weighing 35.5 ± 1.2 g were supplied by Harlan Sprague
Dawley Co. (Indianapolis, IN). All animal experiments were conducted under the
guidelines on humane use and care of laboratory animals for biomedical research
published by the U.S. National Institutes of Health (NIH Publication No. 85-23, revised
1996). The experimental protocols were approved by the Institutional Animal Care and
Use Committee of Virginia Commonwealth University.

2.2 Drugs and chemicals
Rapamycin and wortmannin were purchased from Sigma-Aldrich (St. Louis, MO)
and were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich) for intraperitoneal
injection (i.p.). Final concentrations for rapamycin and wortmannin were 5.55% and
0.25%, respectively.

2.3 Langendorff isolated heart preparation
The methods for the isolated, perfused mouse heart preparation were previously
described in detail (25; 59). Prior to isolating the heart, the animal was weighed and
anesthetized. Anesthesia was prepared by mixing 0.2cc of heparin to protect the heart
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against microthrombi, 0.4cc of pentobarbital, and 0.2cc saline for 4 mice. Each mouse
was injected intraperitoneally with 0.2cc of anesthesia, the equivalent of 100mg/kg of
sodium pentobarbital per mouse. The chest was then opened at the sternum, and the heart
was rapidly removed from the thorax and placed in a small dish containing ice-cold
Krebs-Henseleit (K-H) buffer and heparin (0.1cc per dish), where it was trimmed of
excessive tissue and fat. Using an illuminated magnifier (4X), the aortic opening was
exposed and quickly cannulated on a 20-gauge blunt needle and double loop tied using
no. 5 surgical thread.
The heart was then retrogradedly perfused at a constant pressure of 55 mmHg
through the aorta in a non-recirculating Langendorff apparatus (Figure 2) with modified
K-H buffer containing (in mM) 118 NaCl, 24 NaHCO3, 2.5 CaCl2, 4.7 KCL, 1.2
KH2PO4, 1.2 MgSO4, 11 glucose, and 0.5 EDTA. The K-H solution was pre-filtered by a
micro-filter (Millipore Corp.) with a pore size of 0.45µm diameter, and was continuously
gassed with 95% O2 + 5% CO2 (pH ~ 7.4). The perfusion solution was warmed to 40ºC
through a water-jacketed glass cylinder/heat exchanger system with a warming/cooling
bath and automatic thermal controller (Brinkmann) and was constantly circulated by a
varistaltic water pump (Manostat). The solution was warmed to 40ºC to compensate for
any heat loss experienced as the buffer circulates through the Langendorff apparatus. The
ambient temperature around the heart was also kept at 37 ± 0.2 ºC throughout the
experiment using a 100 Watt heating lamp. A digital thermometer (VWR) continuously
monitored the temperature around the heart. During the no-flow ischemia, K-H buffer
was periodically applied on the heart surface to keep it moist. Hearts demonstrating
persistent arrhythmia during the pre-ischemia period were excluded from further study.

Figure 2:

Langendorff isolated perfused heart system
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2.4 Assessment of heart function
Following the start of perfusion, ventricular function was measured by a forcedisplacement transducer (Grass, Model FT03) attached to the apex of the mouse heart
through a rigid metal hook attached to a no. 5 surgical thread. The resting tension of
the isolated heart was adjusted to 0.3g. Ventricular developed force was continuously
recorded with a PowerLab 8SP computerized data acquisition system (AD instruments)
connected to the force transducer. The coronary flow was calculated by timed collection
of the efflux perfusate at 15 minutes of stabilization (for pre-ischemia value) and again at
15 minutes of reperfusion (for post-ischemia value). The hearts were not electronically
paced.

2.5 Experimental protocol for drug pretreatment and cardiac ischemia-reperfusion
To investigate whether the cardioprotective effect of rapamycin is mediated by
the PI3K/Akt signaling pathway, we administered wortmannin, a PI3K inhibitor, in
addition to rapamycin and the vehicle DMSO, intraperitoneally. As diagrammed in
Figure 3, a total of 29 mice were randomly assigned to four groups. In Group 1 (n=6),
DMSO was administered at two different time points at two different doses. The first
dose was equivalent to the DMSO dilution volume for dissolving WTN (0.25% DMSO in
saline, DMSO-W). The second dose was given an hour later and was equivalent to the
DMSO dilution volume for dissolving rapamycin (5.55% DMSO in saline, DMSO-R). In
Group 2 (n=8) mice received the DMSO-W dose and thirty minutes later received
rapamycin (0.25 mg/kg). Group 3 (n=7) mice were injected with WTN (15µg/kg) and
thirty minutes later were injected with rapamycin (0.25 mg/kg). Group 4 (n=7) was
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treated with WTN (15µg/kg) alone. All hearts were excised and isolated 90 minutes after
the first drug was injected. The hearts were stabilized for 30 minutes after isolation and
subjected to zero-flow ischemia for 20 minutes followed by 30 minutes of reperfusion on
the Langendorff apparatus.

Table 1:

Practical notes for drug preparation

GROUP 1
DMSO
CONTROL

DMSO-R: 50µL DMSO plus 850µL saline=0.9mL. Inject
0.15mL of this solution into each mouse (5.55% [DMSO]).
DMSO-W: 2.5µL DMSO plus 997.5 µL saline = 1mL. Inject 0.2mL
of this solution into each mouse (0.25 % [DMSO]).

GROUP 2
DMSO-W
+ RAPA

DMSO-W: 2.5µL DMSO plus 997.5 µL saline = 1mL. Inject 0.2mL
of this solution into each mouse (0.25 % [DMSO]).
RAPA: 1mL DMSO was used to dissolve 1mg vial of rapamycin.
50µL of this solution plus 850 µL saline =0.9mL. 0.15mL of this
solution was injected into each mouse (5.55% [rapamycin]).

GROUP 3
WTN + RAPA

WTN: 1mL DMSO was used to dissolve 1mg vial of wortmannin.
2.5µL of this solution plus 997.5 µL saline = 1mL. Inject 0.2 mL of
this solution into each mouse (0.25 % [WTN]).
RAPA: 1 mL DMSO was used to dissolve 1mg vial of rapamycin.
50µL of this solution plus 850 µL saline =0.9 mL. 0.15 mL of this
solution was injected into each mouse (5.55% [rapamycin]).

GROUP 4
WTN

WTN: 1mL DMSO was used to dissolve 1mg vial of wortmannin.
2.5µL of this solution plus 997.5 µL saline = 1mL. Inject 0.2 mL of
this solution into each mouse (0.25 % [WTN]).
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Figure 3:
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2.6 Measurement of infarct size
At the end of each experiment, the hearts were immediately removed from the
Langendorff apparatus, dried with a Kimwipe, weighed, and frozen at -20°C. The next
day, the frozen hearts were cut by hand using a surgical blade parallel to the
atrioventricular groove, into 6 to 8 transverse slices of approximately equal thickness
(~1mm). The slices were placed onto an inverted petri dish (Becton Dickinson Labware)
and put face down into the inverted cover of the same petri dish. The heart slices were
stained by incubating them in 10% 2, 3, 5-triphenyl tetrazolium chloride (TTC, Sigma)
solution for 30 minutes at room temperature (~22°C).
In normal myocardium, TTC is converted by dehydrogenase enzyme to a dark red
formazan pigment. On the other hand, infracted myocardium, due to loss of
dehydrogenase enzyme following cell membrane ruptures, does not take up TTC stain
and remains a pale color (58). After staining, the TTC was removed and replaced with
10% formaldehyde for additional 2-4 hours to fix the heart slices. Thereafter, the heart
slices were digitally imaged and total area, cavities, and infracted area were measured
using computer morphometry (Bioquant98) to determine risk area and infarct size. The
risk area was calculated as total ventricular area minus the area of the cavities. The infarct
size was calculated as a percentage of the risk area.

2.7 Protein extraction for Western blot analysis
A separate subset of mouse hearts was used to determine Akt phosphorylation by
rapamycin. Twenty-four (24) mice were anesthetized with sodium pentobarbital
(100mg/kg, i.p.) and hearts were harvested from the control, DMSO-treated or

19
rapamycin-treated groups at the different time points shown in Figure 4. Two non-treated
mice were included as control samples. The hearts were then snap frozen in liquid
nitrogen and immediately stored in –80°C conditions until use. Each heart sample was
crushed using a mortar and pestle. Liquid nitrogen was added as needed during this
process to prevent the tissue sample from defreezing. Once the sample was crushed into a
fine powder, 1.2 mL of ice-cold lysis buffer (Pierce) [containing (in mM) 25 Tris* HCL
pH 7.6, 150 NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS] was added to each
sample tube and kept on ice for 30 minutes. HaltTM Protease Inhibitor Cocktail Kit
(Pierce) and HaltTM Phosphatase Inhibitor Cocktail (Pierce) were also added to the buffer
to protect the sample protein from degradation by endogenous proteases, serine/threonine
phosphatases and tyrosine phosphatases (10 µL of each inhibitor per mL of RIPA buffer
used).
The samples were then homogenized for 3 bursts of 3 to 4 seconds with a
Polytron homogenizer and kept on ice for an additional 15 minutes before being
transferred to Eppendorff tubes and centrifuged at 14,000 rpm (20800g, Eppendorf
Centrifuge 5810R) at 4°C for 10 minutes. The supernatant was separated from the pellet,
divided up into 3 aliquots, and stored in –80°C conditions for further analysis. Protein
content of each heart sample was determined by using 10 mg of bovine serum albumin
(BSA, Sigma-Aldrich) in 10mL of distilled water, forming a BSA stock solution. Taking
1 mL of the solution and adding it to 19 mL of distilled water diluted this stock solution.
This second solution was used to establish a standard curve by adding different amounts
of the BSA solution, water and protein assay dye (Biorad). To determine the protein
concentration of our collected samples, 2 µl of each heart tissue sample were added to
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798 µl of water along with 200 µl of protein assay dye before protein concentration was
determined

by

performing

a

Bradford

assay

using

a

SmartSpecTM

3000

spectrophotometer (Biorad).

Figure 4:

Experimental Protocol 2

30 min
(n=3)

1 hour
(n=3)

2 hours
(n=3)

Excise hearts for Western blotting
DMSO (5.55%) Æ n =9
or
Rapamycin (0.25mg/kg) Æ n=9
or
Non-treated (n=2)
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2.8 Western blot analysis for Akt
Western blot analysis was performed to determine the effect of rapamycin and its
vehicle, DMSO at different post-treatment time points on total Akt and phosphorylated
Akt. Protein samples were combined with an equal volume of a loading buffer solution
made by mixing 25 µl of Laemmli sample buffer (Biorad) and 475 µl 2-mercaptoethanol
electrophoresis purity agent (Biorad). The samples were boiled for 7-10 minutes and
centrifuged for 20 seconds at 14,000 rpm at room temperature before being loaded into
each well on 10% polyacrylamide gels (Biorad). A protein marker (Biorad) was also used
for better identifying the molecular weight of the target protein. The gels were
electrophoresed by a Biorad energy pack for 1 hour at 180 volts using a running buffer
[1X Tris/glycine/SDS (TGS)]. These electrophoresed proteins were transferred from the
gel to nitrocellulose membranes (Biorad) for 90 minutes at 400 mA in 4°C using a
transfer buffer (700 mL water, 200 mL methanol, 100 ml 10X TGS). After transfer, the
nitrocellulose membranes were washed for 5 minutes using 1X Tris-buffered saline
(Biorad) and 5% Tween-20 (Biorad) wash (TBST). The membranes were incubated for 1
hour in 20 mL of a blocking solution [5% blotting milk (Biorad), 20 mL of TBST] at
room temperature to block nonspecific binding sites. Subsequently, the membranes were
incubated with a goat polyclonal antibody (Santa Cruz) specific for total Akt or a rabbit
polyclonal antibody (Santa Cruz) specific for phosphorylated Akt each in 1:1000
dilutions (i.e. 20 µl antibody in 20 mL of blocking solution) on a rocking platform
overnight in a 4°C cold room. The housekeeping gene, β-actin (Santa Cruz), was also
blotted to demonstrate the protein loading condition in each gel lane.
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The next day, the blots were washed thoroughly with approximately 15 mL of
TBST three times for 7-10 minutes each. The blots were then incubated in 1:1000
dilutions of horseradish-labeled anti-goat secondary antibody (Santa Cruz) and anti-rabbit
secondary antibody (Amersham) in 20 mL of blocking buffer for 2 hours at room
temperature. After a thorough wash with TBST again three times for 7-10 minutes each,
the blots were exposed to enhanced chemiluminescence (ECL, Amersham) for a few
seconds, wrapped in plastic wrap and taped down in a developing cassette. In a dark
room, each membrane was exposed to film for approximately one minute for total Akt
and phosphorylated Akt and 20-30 minutes for β-actin before being developed by a film
processor (Kodak). The bands of proteins were visualized and quantified using the Image
J (Image Processing and Analysis in Java) computer program.

2.9 Data analysis and statistics
The difference between groups was analyzed by unpaired t-tests. P < 0.05 was
considered to be statistically significant. All values are expressed as means ± SEM.

RESULTS

3.1 Exclusions
A total of 33 mice were used in the isolated perfused heart study and were used
for data analysis. Among these, 4 hearts (12% of the 33 perfused hearts) were excluded
from various experimental groups due to one or more of the following reasons: damage
of the aorta during cannulation, excessive coronary flow (>6 mL/min), longer cannulation
time (>3 min), arrhythmic heart beat during the equilibration period. Twenty-four mice
were used for Western blot analysis and no mice were excluded from this experiment.

Table 2:

Morphometric characters of mice used in isolated heart
experiment

Experimental Groups

Body weight (g)

Heart Wet Weight (mg)

DMSO (n=6)

33.5 ± 3.5

237 ± 15

RAPA (n=8)

38.6 ± 3.5

230 ± 11

WTN+RAPA (n=7)

34.7 ± 0.8

203 ± 6

WTN (n=7)

36.8 ± 0.6

221 ± 9

Values shown as means ± standard error of mean (SEM).
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3.2 Rapamycin preconditioning reduced infarct size
Previously, rapamycin has been shown to have a cardioprotective effect in the
isolated mouse heart model. This was demonstrated by a reduction in infarct size in
rapamycin-treated mice (25). As shown in Figure 5A, the infarct size in DMSO control
mice was 33.8 ± 2.0% of risk area. As targeted, rapamycin significantly (P=0.0149)
decreased infarct size to 19.3 ± 4.1%, a 43% reduction compared to the DMSO control
group. Infarct size was calculated as a percentage of total risk area, a measured area that
did not vary among the four experimental groups (Figure 5B). This degree of protection
by rapamycin is comparable to the highly selective mitochondrial KATP channel opener,
diazoxide (54% decrease). Like rapamycin, diazoxide reduced infarct size from 27.8 ±
4.2% to 12.9 ± 1.2% after pharmacological preconditioning with diazoxide (39).

3.3 Wortmannin blocked rapamycin protection
Wortmannin has been used effectively in past studies as a specific PI3K inhibitor
(44), blocking signaling to all downstream effectors including Akt (11). To verify the
potential Akt mediation of rapamycin protection, wortmannin was used to block PI3K
and therefore all proteins downstream including Akt. Figure 5A illustrates the similarity
in infarct size between the DMSO control and Group 3 mice which were treated with
wortmannin and rapamycin (29.3 ± 4.8%). As predicted, wortmannin effectively
abrogated rapamycin-mediated cardioprotection.
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3.4 Wortmannin alone protected the heart
Interestingly, there was a significant (P=0.0403) reduction in infarct size (24.7 ±
3.2%) in the group treated solely with wortmannin (Figure 5A). This result suggests that
wortmannin may have cardioprotective capabilities against I-R injury.
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Figure 5A: Myocardial infarct size
Mice were divided into 4 groups and hearts were isolated and perfused as
described in chapters 2.3 and 2.5. Infarct size was significantly reduced in two
different groups, RAPA-treated and WTN-treated mice (*P<0.05 vs. DMSO).
Wortmannin also proved to effectively block rapamycin protection.

Figure 5B: Risk area
Risk area was calculated as a percentage of total area and was similar in all
four experimental groups.
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A

B

C

D

Figure 6:

Representative digital images of stained heart slices
A) DMSO-treated heart (n=6)
B) RAPA-treated heart (n=8)
C) WTN- and RAPA-treated heart (n=7)
D) WTN-treated heart (n=7)
Heart slices were stained with TTC and fixed with formalin. Viable
tissue remains red, whereas infarcted tissue appears pale and colorless.
The DMSO control heart (A) has much larger infarcted area as compared
to the RAPA-treated heart (B), showing healthy myocardium and little
infarcted tissue. The same can be said of WTN-treated hearts (D) which
show very little pale tissue. On the other hand, the group treated with
WTN and RAPA (C) has a measurable amount of dead tissue which
suggests that WTN successfully blocked rapamycin-induced protection.
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3.5 Cardiovascular function
Pre-ischemic and post-reperfusion values of hemodynamic and cardiovascular
function of the isolated perfused hearts are summarized in Table 2. In order to study the
effect of rapamycin on heart function as well as infarct size we used the isolated heart
model, eliminating the influence of circulating factors on the heart. Rate-force product
(RFP) is a measured estimation of cardiac function and is calculated as developed force x
heart rate (g x beats/minute). When RFP was calculated as a percentage of baseline preischemia values, there was no significant change between all four experimental groups
(Figure 7). However, observation of the individual RFP values in Table 2 shows a
significant decrease in RAPA-treated groups post-reperfusion compared to DMSOtreated groups post-reperfusion (P=0.0099).

Figure 8 shows a significant decrease in developed force (DF) post-reperfusion,
between mice treated with DMSO and those treated with RAPA (P= 0.0268). DF is the
amplitude of heart contractility independent of heart rate. A constant trend of reduced DF
after ischemia can be observed in all the experimental groups.

Coronary effluent was measured for one minute after 15 minutes of stabilization
and again 15 minutes after reperfusion as an estimation of coronary flow in vivo. There
was no significant change in coronary flow from the pre-ischemic baseline measurement
to the post-reperfusion measurement in RAPA-treated mice due to variability within this
group (Figure 9B). Nevertheless, there is a noticeable increase in coronary flow in the
RAPA-treated group compared to the DMSO-treated group during both pre-ischemia and
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post-reperfusion (Figure 9A). An unexpected result, illustrated in Figure 9A, is a
significant elevation of coronary flow in WTN-treated groups, pre-ischemia (P= 0.05)
and post-reperfusion (P= 0.0414) compared to the DMSO control group. This result adds
to and explains the increased RFP in WTN-treated groups.

Table 2:

Values of hemodynamic and contractile parameters of isolated perfused hearts after 15 minutes of
stabilization (pre-ischemia) and after 30 minutes of reperfusion

Pre-ischemia

HR (beats/min)
DF (g)

DMSO

RAPA

WTN+RAPA

WTN

DMSO

RAPA

321 ± 29

350 ± 22

359 ± 32

350 ± 16

350 ± 27

325 ± 36

0.82 ± 0.14

RFP(g beats/min)
CF (mL/min)

At 30 minutes of reperfusion

278 ± 67
1.38 ± 0.13

0.61 ± 0.12
214 ± 44
2.39 ± 0.52

0.56 ± 0.20
171 ± 48
1.86 ± 0.46

0.76 ± 0.16

0.67 ± 0.10

258 ± 48
1.81 ± 0.15

c

0.36 ± 0.07
b

231 ± 31

108 ± 22

1.29 ± 0.09

3.02 ± 0.89

a

WTN+RAPA

WTN

396 ± 28

358 ± 12

0.50 ± 0.20

0.55 ± 0.16

178 ± 67

189 ± 49

1.71 ± 0.45

1.83 ± 0.20d

a

P < 0.05 vs. DMSO post-reperfusion (unpaired t test)
P <0.05 vs. DMSO post-reperfusion (unpaired t test)
c
P <0.05 vs. DMSO pre-ischemia (unpaired t test)
d
P <0.05 vs. DMSO post-reperfusion (unpaired t test)
b

HR, heart rate; DF, developed force; RFP, rate-force product; CF, coronary flow. Values shown are means ± SEM. Experimental groups: 1) DMSO =
mice treated with vehicle control (0.25% DMSO, i.p.) 90 min and 30 min (5.5% DMSO, i.p.) prior to ischemia-reperfusion (I-R); 2) RAPA = mice treated with
vehicle 90 min (0.25% DMSO, i.p.) before I-R and with rapamycin (RAPA, 0.25mg/kg, i.p.) 30 min prior to I-R;
wortmannin (WTN, 15µg/kg, i.p.) 90 min prior to IR and with RAPA (0.25mg/kg, i.p.) 30 min prior to IR;

3) WTN + RAPA = mice treated with

4) WTN = mice treated with WTN (15µg/kg, i.p)

90 min prior to I-R.
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Figure 7:

DMSO
n=6

RAPA
n=8

WTN+RAPA WTN
n=7
n=7

Rate-force product
There was no significant difference in the recovery of cardiac
function (rate-force product) among groups. Rate-force product
was taken as a percentage of the pre-ischemia baseline value.
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Figure 8:
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Developed force
Post reperfusion, a significant difference in developed force was
observed between DMSO-treated and RAPA-treated groups
(*P<0.05).
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Figure 9A: Coronary flow
Mean coronary flow pre-ischemia (after 15 min stabilization and
post-reperfusion (after 15 min of reperfusion). There was no
significant difference in coronary flow among the groups, preischemia or post-ischemia except in the group treated with WTN.
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Figure 9B: Percent change of coronary flow
The percent change of coronary flow was calculated from the preischemia baseline to post-reperfusion. There was no significant
difference in the change in coronary flow from baseline to
reperfusion among the groups. However, a marked difference can
be noted between DMSO- and RAPA-treated groups.
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3.5 Western blot analysis of Akt
IPC protects the heart by phosphorylating the prosurvival kinase, Akt (4). Mice
were pharmacologically preconditioned with the DMSO (n=3) and rapamycin (n=3).
Hearts were then harvested after 30 minutes, 1 hour, and 2 hours of pretreatment. The
phosphorylation state of Akt in the prosurvival pathway was then examined via Western
blot analysis. Hearts in a non-treated control group (n=2) were also blotted for changes in
phosphorylation of Akt at Ser473, although the DMSO-treated group was considered as the
true control group as DMSO was used as the vehicle for rapamycin administration.
Representative western blots are displayed in Figure 10. After careful densitometry
measurement of completed Western blots, no appreciable difference in the
phosphorylation state of Akt versus total Akt was observed between any of the time
points or experimental groups (Figure 11). Total Akt was also blotted for although these
protein levels did not vary, suggesting that any changes in kinase phosphorylation were
not due to changes in total kinase levels. All in all Western blot analysis did not confirm
any change in Akt phosphorylation.

2 hours

1 hour

30 min

2 hours

1 hour

30 min

Control
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total Akt
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total Akt
p-Akt (Ser 473)

C

total Akt

Control

DMSO

Rapamycin

Figure 10: Western blot analysis of Akt
This analysis was performed in triplicate for DMSO- and
RAPA-treated groups (A, B, C). Each Western blot is
shown as a pair with phosphorylated Akt Ser473 (top) and
total Akt (bottom).
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Figure 11: Western blot densitometry
Measurements were calculated as a ratio of phosphorylated Akt to
total Akt which are similar among all groups and time points. The
phosphorylation state of Akt was compared with densitometric
analysis by the Image J software program. Bar graphs represent the
mean ± SEM.

DISCUSSION

4.1 Present study
The concept that pharmacological preconditioning with rapamycin protects the
heart against I-R injury was first introduced by Khan et al. in 2006 from our laboratory
(25). However, the cellular and molecular mechanism that mediates this protection
remains elusive. The aim of this study was to define the signaling mechanisms underlying
the cardioprotective action of rapamycin. We postulated that Akt mediates rapamycininduced protection via a positive feedback loop to Akt from mTOR, which is inhibited by
rapamycin. We were particularly interested in studying the role of Akt because this
signaling molecule has been shown to be activated by IPC (18; 26) and by IPC mimetics
such as insulin (22) which initiate the PI3K/Akt prosurvial signaling cascade. In these
studies, cardioprotection is induced through mTOR and p70S6K activation, resulting in
an increase in translation and protein synthesis.

4.2 Rapamycin-induced cardioprotection
In the current investigation, mice were pre-treated with rapamycin (0.25mg/kg)
after which hearts were subjected to ischemia and reperfusion in the isolated perfused
heart model. The rationale for using the isolated heart model was to eliminate all
circulating factors that exist in vivo and demonstrate the direct effect of rapamycin on the
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post-ischemic recovery of function and infarct size in the intact heart. Our results show
that rapamycin significantly reduced infarct size as compared to DMSO-treated control
hearts. However, there was no improvement in the recovery of heart function or
developed force (heart contractility), which essentially confirms the data from our
previous study (25). Contrarily, we observed an increase in coronary flow in rapamycintreated mice before ischemia and after reperfusion, which indicates a possible
vasodilating property of rapamycin.
Rapamycin is a well-known inhibitor of mTOR and is usually used to block
signaling in the prosurvival pathway, which abolishes cardioprotection (16; 22). This
property of rapamycin presents a challenge in explaining why the current study
contradicts precedent research. First, the inhibition of mTOR by rapamycin results in
decreased protein synthesis, one of the highest ATP-consuming cellular processes. This
could potentially direct more of the cell’s energy reserve and resources to protecting the
heart against ATP-depletion during ischemia. In accordance with this concept, Granville
et al. showed that inhibition of mitochondrial protein synthesis with chloramphenicol in
isolated perfused rat hearts reduced infarct size (12). Protection may also be animal
model specific, but little additional research has been done with rapamycin and the
isolated perfused mouse model to prove this conclusion.

4.3 Rapamycin-induced cardioprotection is PI3K-dependent and wortmannin alone leads
cardioprotection
In the present study, wortmannin blocked cardioprotection conferred by
rapamycin as demonstrated by a similar degree of infarct size as the DMSO control
group. This suggests that PI3K is involved in mediating rapamycin-induced signaling. An
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unexpected yet tentative finding in the current study was that wortmannin alone conferred
protection in the heart against ischemia-reperfusion as demonstrated by a significant
decrease in infarct size (compared to the DMSO control group). The exact mechanism of
this protection is not clear although it can be explained by known actions of wortmannin.
As a potent and widely used PI3K inhibitor (44), wortmannin blocks all downstream
signaling targets of this protein. For example, it has been previously shown that
wortmannin directly inhibits signaling functions of mTOR by irreversibly inhibiting its
autokinase activity (4). Moreover, varying levels of mTOR activation in a lymphoma cell
line was associated with different concentrations of wortmannin treatment. The mTOR
signaling was attenuated when cells were exposed to sub- or low- micromolar
concentrations of wortmannin (4). Because of the attenuated mTOR signaling as a result
of wortmannin treatment, there may be reduced protein synthesis similar to rapamycin
treatment, which could potentially lead to more focused activation of cell survival
machinery.
Also, the specificity of wortmannin solely as a PI3K inhibitor must be questioned.
Research by Davies et al. demonstrated wortmannin inhibition of other members of the
PI3K superfamily in addition to PI3K itself (9). Wortmannin was found to be an inhibitor
of SmLCK or smooth muscle myosin light chain kinase (37), although to a lesser degree
than PI3K. Wortmannin also inhibited GSK3β also to a significant yet lesser degree than
PI3K (8). Thus the protection against ischemia-reperfusion by wortmannin observed in
the present study could by an inadvertent result of the inhibition of other kinases besides
PI3K.
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Lastly, the Ras-Raf-MEK-Erk signaling cascade has been shown to be inhibited
by the PI3K/Akt signaling cascade with specific cross-talk between Akt inhibiting Raf-1
(Figure 12) (35; 45). When PI3K was blocked by wortmannin, Akt signaling was blocked
as well, including inhibition of Raf-1. This could have liberated the Ras-Raf-MEK-Erk
pathway to confer cardioprotection. Although there is no clear evidence available in the
literature about the role of wortmannin as being cardioprotective, this leaves an area of
research open to further studies.

4.4 Akt not upregulated by rapamycin
Previous studies have shown increased Akt phosphorylation after IPC. The
overexpression of constitutively active Akt was discovered to reduce infarct size and
apoptosis (26). Also, Li et al. reported that rapamycin significantly increased Akt
phosphorylation in cardiomyocytes (30). Because of the anti-necrotic and anti-apoptotic
effect of rapamycin in adult cardiomyocytes (25), we postulated that the drug may exert
such cardioprotective effects through upregulation of Akt. In the present study, we
monitored phosphorylation of Akt following treatment with rapamycin. Surprisingly, Akt
was not phosphorylated significantly in both DMSO control and rapamycin-treated
hearts. We evaluated the phosphorylation states of Akt at Ser 473 after 30 minutes, 1 hour
and 2 hours following rapamycin treatment in order to carefully track the phosphorylation
time-course of this signaling molecule. Therefore, it is unlikely that this treatment
protocol might have missed the transient activation of Akt unless it occurred in less than
30 minutes after treatment with rapamycin. Another possibility is that Akt may not be
upregulated at all by rapamycin without an ischemic trigger.
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Finally, as mentioned earlier there is a possibility that Akt may work in concert
with Erk in a parallel pathway to reach the “threshold” of mTOR or p70S6K
inactivation/activation by rapamycin. Hausenloy et al. originally reported that, the
PI3K/Akt and MEK-Erk signaling cascades exhibit cross-talk when they are activated by
IPC. When Akt signaling was inhibited by the PI3K inhibitor LY294002, Erk in the other
cascade pathway was activated. In turn, Akt was activated when PD98059 was used to
inhibit the MEK-Erk pathway (17-19). In response to I-R injury, these kinase cascades
activate protection through their anti-apoptotic effectors. Erk activation was also shown
to be insensitive to inhibitors of PI3K such as wortmannin (9). Further evaluation on the
effect of rapamycin on phosphorylation of Erk and MEK are needed to support this
argument.
It is also possible that rapamycin might have another intracellular target that
mediates its cardioprotection besides mTOR. Because wortmannin blocked rapamycin
protection and Akt phosphorylation was not influenced by rapamycin, it can be implied
that PI3K is involved in mediating signaling and not necessarily Akt. Hypothetically,
rapamycin could directly target PI3K and whatever lies downstream of PI3K other than
Akt for example, through a PDK1-PKC-dependent pathway. As a result, PI3K might
have a direct signaling link to the Ras-Raf-MEK-Erk pathway. Rapamycin is known to
inhibit mTOR and attenuate protein synthesis leaving more energy for prosurvival.
Contrary to our previous hypothesis of a feedback loop between mTOR and Akt, there
may be a signaling loop between mTOR and PI3K instead (see Figure 12).
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4.5 Future studies
Obviously, more thorough investigations are required to demonstrate the effect of
rapamycin on Akt phosphorylation. This will be accomplished by monitoring Akt
phosphorylation on hearts preconditioned with rapamycin and subjected to ischemiareperfusion in the isolated perfused heart model. In the present investigation, we were
interested in studying the role of rapamycin in Akt phosphorylation without the
confounding effect of ischemia-reperfusion. Other kinases in PI3K/Akt must also be
blotted for such as PDK1, mTOR, and p70S6K along with kinases in the prosurvival
pathways such as Erk and Raf also need to be investigated to see if they have a role in
cardioprotection with rapamycin.

4.6 Conclusions
Although preventive medicine will most effectively control the prevalence of
heart disease and myocardial infarctions, limitations such as the expenses and availability
of medicine impairs this approach. Novel medical treatments that will limit the extent of
damage caused by a myocardial infarction are urgently needed. Cellular protection or
tolerance against ischemia is coming to the forefront of research in order to find new
methods for treating cardiovascular diseases. This study acknowledges rapamycin as an
important pharmacological agent that protects the heart against I-R injury. To our
knowledge this is the first study implicating divergent roles of PI3K and Akt in the
signaling mechanism of rapamycin-induced cardioprotection in the isolated perfused
mouse model. Development of this model lays the groundwork for investigating other
signaling pathways for the benefit and management of acute myocardial infarction.
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Figure 12: Final hypothetical signaling pathway
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